Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma.
Maryam SafariLuigi ScottoAgnes BassevilleThomas LitmanHaoran XueLuba PetrukhinPing ZhouDiana V MoralesChristopher DamociMingzhao ZhuKenneth HullKenneth P OliveTito FojoDaniel RomoSusan E BatesPublished in: bioRxiv : the preprint server for biology (2024)
Pancreatic ductal adenocarcinoma, a significant clinical challenge, could benefit from the latent potential of epigenetic therapies like HDAC inhibitors-(HDIs), typically limited to hematological malignancies. Our study shows that a synergistic low dose combination of HDIs with an eIF4A-inhibitor in pancreatic cancer models results in marked pre-clinical efficacy, offering a promising new treatment strategy.